|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Emory University |
|---|---|
| Information provided by: | Emory University |
| ClinicalTrials.gov Identifier: | NCT00209131 |
Purpose
The majority of kidney stones are treated with shock wave lithotripsy (SWL). We are examining if the medication Flomax will result in improved stone passage rates following SWL.
| Condition |
|---|
|
Urolithiasis |
| Study Type: | Observational |
| Study Design: | Longitudinal, Defined Population, Prospective Study |
| Official Title: | Efficacy of Flomax to Improve Stone Passage Following Shock Wave Lithotripsy |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Contacts and Locations| Contact: Kenneth Ogan, MD | 404-778-3038 | kenneth_ogan@emoryhealthcare.org |
| United States, Georgia | |
| Emory University | Recruiting |
| Atlanta, Georgia, United States, 30322 | |
| Contact: Kenneth Ogan, MD 404-778-3038 kenneth_ogan@emoryhealthcare.org | |
| Principal Investigator: | Kenneth Ogan, MD | Emory University |
More Information
| Study ID Numbers: | IRB ID: 128-2005 |
| Study First Received: | September 14, 2005 |
| Last Updated: | February 7, 2006 |
| ClinicalTrials.gov Identifier: | NCT00209131 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
urolithiasis |
|
Urologic Diseases Urolithiasis |